Colorectal cancer (CRC) remains a significant clinical challenge, especially when tumors create an immune-excluded microenvironment. This specific phenotype often limits the success of PTPRN2 colorectal cancer immunotherapy and standard PD-1 blockade. Recent systematic profiling of 106 protein tyrosine phosphatases (PTPs) has identified PTPRN2 as a primary driver of this resistance.

Understanding PTPRN2 Colorectal Cancer Immunotherapy Challenges

Integrated analyses across patient cohorts show that PTPRN2 is highly enriched in tumors that resist immunotherapy. Specifically, researchers identified three PTP-based molecular subtypes. Among these, the immune-excluded Cluster 2 shows the highest resistance to treatment. Consequently, high PTPRN2 expression serves as a strong biomarker for anti-PD-1 non-response.

Mechanism: STAT1 Dephosphorylation and CIITA Downregulation

Functional studies reveal that PTPRN2 does more than promote cell proliferation and invasion. Mechanistically, it suppresses tumor-intrinsic MHC-II expression. PTPRN2 promotes the dephosphorylation of STAT1 at the Y701 residue, which effectively inhibits STAT1 activation. This inhibition subsequently downregulates the expression of CIITA, the master regulator of MHC-II. Therefore, the tumor cells lose their ability to present antigens, allowing them to evade T-cell detection.

Therapeutic Potential of Targeting PTPRN2

Fortunately, restoring the immune response is possible. PTPRN2 knockdown effectively restores MHC-II levels and enhances the activation of CD4+ and CD8+ T-cells in organoid models. Furthermore, in vivo tests confirm that reducing PTPRN2 increases T-cell infiltration into the tumor. Notably, combining PTPRN2 inhibition with PD-1 blockade provides more effective tumor suppression than monotherapy. Additionally, IL-15 can rescue STAT1 phosphorylation, offering another potential therapeutic axis to improve outcomes in CRC patients.

Conclusion

Collectively, these findings highlight PTPRN2 as a major regulator of immune exclusion. Targeting this phosphatase may transform the treatment landscape for colorectal cancer by making cold tumors sensitive to immunotherapy again.

Frequently Asked Questions

How does PTPRN2 contribute to immunotherapy resistance in CRC?

PTPRN2 silences tumor-intrinsic MHC-II expression by dephosphorylating STAT1. This action prevents proper antigen presentation, which creates an immune-excluded environment where T-cells cannot target the cancer cells.

Can existing therapies be combined with PTPRN2 inhibition?

Yes. Research indicates that combining PTPRN2 knockdown with PD-1 blockade is significantly more effective than either treatment alone. Moreover, cytokines like IL-15 may help restore the immune signaling pathways blocked by PTPRN2.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Clinical decisions should be made by qualified healthcare professionals based on individual patient assessment. Refer to the latest local and national guidelines for clinical practice.

References

1. Cao Y et al. PTPRN2-mediated silencing of tumor-intrinsic MHC-II promotes immune-excluded tumor microenvironment in colorectal cancer. Cancer Genet. 2026 May 15. doi: undefined. PMID: 42139752.

2. Fu MS et al. HOXD13 promotes the malignant progression of colon cancer by upregulating PTPRN2. Cancer Medicine. 2021;10(16):5524–5533. doi: 10.1002/cam4.4078.

3. Katkeviciute E et al. Protein tyrosine phosphatase non-receptor type 2 controls colorectal cancer development. JCI. 2021;131(1):e140281. doi: 10.1172/JCI140281.